Search Results for “ breast cancer” – Page 10 – media

Culmination Bio and BillionToOne partner to advance cancer diagnosis

Culmination Bio has announced a partnership with BillionToOne to develop and advance diagnostic tests in oncology that are accessible to all. Both companies will work together to facilitate the development and validation of robust and impactful oncology diagnostics. According to the Centers for Disease Control, skin cancer is currently the most common type of cancer in the US, responsible for more than 9,500 new cases every day, followed by lung cancer, prostate cancer and breast cancer. The molecular diagnosis company, BillionToOne, is developing these new diagnostics in an effort to address the challenges associated with accurately profiling cancer to assess the best treatment and monitor responses to determine the effectiveness of the cancer treatment. As part of the agreement, the data and technology company will use its Data Lake and patient recruitment abilities to help BillionToOne validate the clinical performance of two new diagnostic tests: Northstar Select, an ultra-sensitive, NGS-based ...
- Source: drugdu
- 145
- April 11, 2024
Alliance Healthcare launches cancer symptom referral scheme in UK pharmacies

Around three million people in the UK were estimated to be living with cancer in 2022 Alliance Healthcare has announced it has opened access to UK pharmacies of its ‘Not Normal for You?’ (NNFY) cancer symptom referral scheme to allow pharmacists to refer patients showing potential cancer symptoms to their GPs. The expansion follows the successful launch of the scheme across Alphega Pharmacy’s network, a brand under Alliance Healthcare comprising a network of independent pharmacies across the world. According to Macmillan Cancer Support, around three million people in the UK were estimated to be living with cancer in 2022. The most common cancers in the UK are breast cancer, which accounts for 15% of all cases, followed by prostate cancer (14%), lung cancer (13%) and bowel cancer (11%). As part of the rollout, Alliance Healthcare will provide pharmacies with marketing materials such as leaflets and referral cards, free of charge, ...
- Source: drugdu
- 83
- April 10, 2024
Jazz Pharmaceuticals Completes Biologics License Application for Zanidatamab for HER2-Positive Metastatic Biliary Tract Cancer

Don Tracy, Associate Editor Approval would mark first HER2-targeted therapy for biliary tract cancer in the United States. Jazz Pharmaceuticals announced that it has completed its Biologics License Application (BLA) for zanidatamab, an investigational bispecific antibody treatment targeting HER2-positive metastatic(BTC). Aiming for accelerated approval, zanidatamab has the potential to be the first HER2-targeted therapy indicated for BTC in the United States. According to the company, the BLA was based on findings from the Phase IIb HERIZON-BTC-01 trial for zanidatamab. The primary study endpoint of confirmed objective response rate (cORR) by independent central review (ICR) was deemed a success, as the 80 enrolled patients demonstrated a cORR of 41.3%. The HERIZON-BTC-302 Phase III started recently and is currently in the process of enrollment.1 “This important milestone brings us one step closer to delivering zanidatamab, a targeted treatment option, to patients living with HER2-positive BTC, a type of cancer that is associated ...
- Source: drugdu
- 133
- April 5, 2024
Strand Therapeutics develops new class of mRNA molecules for cancer

The self-replicating mRNA molecule could be used in cancer and potentially a broad range of other diseases Strand Therapeutics, a Massachusetts Institute of Technology (MIT) spinout, has developed a new class of advanced mRNA molecules for more targeted and powerful treatments for cancer. The new class of mRNA molecules is designed to sense what type of cells they encounter in the body and express therapeutic proteins once they have entered diseased cells. Most next-generation cancer immunotherapies are based on recombinant proteins, which are challenging to deliver to specific targets in the body and do not remain active for long enough to create a durable response. Strand has developed the world’s first mRNA programming language to improve mRNA molecules’ ability to sense their environment and generate targeted responses where needed most, allowing the company to specify the tissues its mRNAs express proteins in. In addition, the company uses techniques such as ...
- Source: drugdu
- 80
- April 1, 2024
Clinical Trial of Keytruda and Lynparza Combination Fails to Meet Primary Endpoint for Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer

Don Tracy, Associate Editor Despite not having a positive outcome, safety profiles for Keytruda and Lynparza were consistent with previous findings. Merck revealed that its Phase III KEYLYNK-006 clinical trial, which tested a combination of Keytruda and Lynparza for the treatment of a subset of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), failed to meet the primary endpoint of improving overall survival (OS) and progression-free survival (PFS). According to the company, its trial compared Keytruda combined with chemotherapy with an additional round of Keytruda plus Lynparza vs. Keytruda with chemotherapy followed by maintenance chemotherapy. However, the safety profiles for both treatments were reported to be consistent with previous findings. Moving forward, Merck said that it plans on continuing to analyze data to share at a later date.1 “As lung cancer continues to be the leading cause of cancer death worldwide, we are committed to exploring Keytruda-based combinations and ...
- Source: drugdu
- 138
- March 26, 2024
Biomechanical model simulates breast tumor growth

Scientists from Universidad Carlos III de Madrid (UC3M) and Johns Hopkins University (JHU), in the USA, have analyzed the growth of breast tumors from a biomechanical perspective and have created a computational model that simulates the invasion process of cancer cells, depending on the characteristics of the surrounding tissue and cell junctions, among other parameters. This type of model will help predict the evolution of a tumor in patients from its mechanical properties (stiffness, density, etc.) of the surrounding microenvironment, which can be determined through a biopsy or imaging techniques. The growth process of a solid tumor involves its expansion through the surrounding tissue, usually composed of a fibrillar matrix (for example, collagen). Its expansion depends on many factors such as the total number of tumor cells, their volume and stiffness, their access to nutrients, and the mechanical properties of the tissue in which they are developing. Supported by experimental ...
- Source: drugdu
- 106
- March 25, 2024
NHS to ensure people eligible for very high-risk breast screening are referred

Secondary breast cancer is an important risk factor after receiving radiotherapy for Hodgkin lymphoma NHS England has responded to the recent ministerial statement by newly establishing the Very High Risk (VHR) Pathway through the NHS Breast Screening Programme that invites eligible women for annual testing. The NHS is contacting 1,487 women who are at increased risk of breast cancer due to having radiotherapy involving their chest for Hodgkin lymphoma. Hodgkin lymphoma is an uncommon cancer that develops in the lymphatic system. An important risk factor after radiotherapy can include the development of secondary breast cancer, the most common cancer in the UK. Recently, the minister of state for health and secondary care, Andrew Stephenson, said in his statement that NHS England contacted a group of women who were at “very high risk of breast cancer who have been eligible for annual MRI checks, but who may not have been routinely ...
- Source: drugdu
- 151
- March 9, 2024
Groundbreaking Blood Test Offers Early Pancreatic Cancer Diagnosis

Pancreatic cancer ranks as the third leading cause of cancer-related deaths, primarily due to its late detection. Early discovery of the disease, while it’s still treatable, could significantly impact survival rates. For more than a century, scientists have sought to link cancer with cellular energy production and metabolism. The advent of quantitative mass spectrometry has enabled the testing of many such theories. Now, for the first time, researchers have utilized targeted mass spectrometry to demonstrate that pancreatic cancer stems from changes in cellular metabolism that are detectable using a simple blood test. This method could lead to more precise and earlier diagnoses of pancreatic cancer than currently possible with tumor markers or imaging techniques, potentially paving the way for more timely and appropriate therapeutic interventions. In contrast to genomic approaches that measure DNA for early detection and often struggle with false positives and negatives, mass spectrometry can measure extremely low ...
- Source: drugdu
- 170
- March 6, 2024
Bavarian Nordic Hones Infectious Disease Focus by Dropping Cancer Vaccine R&D

Bavarian Nordic will concentrate on its portfolio and pipeline of infectious diseases vaccines, including top seller Jynneos, approved for mpox and smallpox. The company only had one clinical-stage cancer vaccine program. By FRANK VINLUAN The mpox outbreak is a memory, but Bavarian Nordic, maker of the only FDA-approved vaccine for the pathogen behind this viral infection, turned skyrocketing demand for its product into record revenue. With that growth comes a need to focus, and the pure-play vaccines company is getting out of the business of developing vaccines for cancer. Bavarian Nordic’s lone cancer vaccine candidate, TAEK-VAC, had reached Phase 1 testing as a potential treatment for chordoma or HER2-positive breast cancer. But this program had also reached the point where further investment is needed, and Bavarian Nordic decided it needs to focus its R&D efforts on infectious disease, the Denmark-based company said Wednesday in its announcement of preliminary 2023 financial ...
- Source: drugdu
- 157
- February 23, 2024
Daiichi Sankyo and AstraZeneca’s lung cancer antibody set for FDA review

It is shaping up to be a big year for AstraZeneca in lung cancer treatments. Following another approval win for its blockbuster immunotherapy drug Tagrisso (Osimertinib) in non-small cell lung cancer (NSCLC), another drug could be on the way later this year. The US Food and Drug Administration (FDA) has accepted for review Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan (Dato-DXd) for the treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy, as per a 19 February press release. The outcome of the FDA’s decision will only be known later this year, with a Prescription Drug User Free Act (PDUFA) date set for 20 December 2024. AstraZeneca and Daiichi Sankyo’s Dato-DXd is a TROP2-directed antibody-drug conjugate (ADC). TROP2 is a protein highly expressed in many types of lung cancers. The drug has demonstrated positive results in the Phase III TROPION-Lung01 ...
- Source: drugdu
- 137
- February 21, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.